Management team
I believe good science equals good business. SiSaf is the culmination of more than 25 years that I spent in drug delivery research and senior management.
As an immunologist, I spent two decades understanding the modes of action in disease and looking for treatments. I’ve seen how ProSilic bio-courier technology can intervene and cure.
My 20 years’ experience in analytical techniques and drug delivery research helped boost the development of ProSilic right from the start.
SiSaf has a fantastic opportunity to develop and commercialise its Bio-Courier technology for a range of therapies, but particularly its potential in gene therapy. As an experienced finance professional, it is great to be able to work with Suzanne and the team to realise that value growth.
Over my many years in health care marketing I’ve had lots of drug delivery systems cross my desk but all of them fell short, until I was introduced to SiSaf. I was so impressed I joined the company.
I am particularly excited about the development of affordable therapies for autosomal dominant diseases with Bio-Couriers. I believe non-viral gene therapies have the potential to become standard clinical practise.
Advisors
Coming Soon
Distinguished Professor of Medicine and Medical and Molecular Genetics and is the director of the division of Endocrinology and Metabolism. Indianan University School of Medicine
Professor of Applied Pharmaceutical Chemistry. Professor of Pharmaceutical Technologies. University of Palermo (UNIPA)
Director of the Biomedical Research Institute at Ulster University
Frost Professor of Ophthalmology and Chairman of the Academic Department of Ophthalmology at St. Thomas’ Hospital
Medical Director, Board-Certified Dermatologist, Fellow American Society for Mohs Surgery.
Board
I believe good science equals good business. SiSaf is the culmination of more than 25 years that I spent in drug delivery research and senior management.
I led the Series A investment in SiSaf not just because of their innovative platform technology, but also the passion of the people behind it.
As Croda’s Head of Global R&D, I value the expertise and dedication that SiSaf’s team bring to their breakthrough technology.
Ever since I led the investment in Baidu and became its largest shareholder on behalf of Dfj Eplanet, I’ve been on the lookout for companies with game changing technologies. SiSaf is one of those game changers.
During my 25 years in the financial industry, SiSaf is one of the most exciting biotech companies I’ve come across.
I’m extremely proud to have spotted the company’s global potential in its early days.
As Director of Research and Impact for one of SiSaf’s first investors, I’ve followed the company’s extraordinary progress from day one.